GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV1) » Definitions » Shiller PE Ratio

DBV Technologies (FRA:DBV1) Shiller PE Ratio : (As of May. 07, 2025)


View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


DBV Technologies Shiller PE Ratio Historical Data

The historical data trend for DBV Technologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Shiller PE Ratio Chart

DBV Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DBV Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DBV Technologies's Shiller PE Ratio

For the Biotechnology subindustry, DBV Technologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DBV Technologies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Shiller PE Ratio falls into.


;
;

DBV Technologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

DBV Technologies's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, DBV Technologies's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.202/120.1600*120.1600
=-1.202

Current CPI (Mar. 2025) = 120.1600.

DBV Technologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201112 0.000 97.800 0.000
201206 0.000 98.780 0.000
201212 0.000 99.100 0.000
201306 0.000 99.700 0.000
201312 0.000 99.800 0.000
201406 0.000 100.180 0.000
201412 0.000 99.860 0.000
201506 0.000 100.440 0.000
201512 0.000 100.040 0.000
201606 0.000 100.630 0.000
201612 0.000 100.650 0.000
201706 0.000 101.320 0.000
201712 0.000 101.850 0.000
201806 0.000 103.370 0.000
201809 -7.334 103.560 -8.510
201812 -8.123 103.470 -9.433
201906 0.000 104.580 0.000
201909 -3.699 104.500 -4.253
201912 -4.825 104.980 -5.523
202003 -3.575 104.590 -4.107
202006 -3.907 104.790 -4.480
202009 -2.377 104.550 -2.732
202012 -2.959 104.960 -3.388
202103 -2.268 105.750 -2.577
202106 -2.324 106.340 -2.626
202109 -1.870 106.810 -2.104
202112 -1.106 107.850 -1.232
202203 -1.362 110.490 -1.481
202206 -1.656 112.550 -1.768
202209 -0.909 112.740 -0.969
202212 -2.124 114.160 -2.236
202303 -1.027 116.790 -1.057
202306 -1.200 117.650 -1.226
202309 -0.796 118.260 -0.809
202312 -0.504 118.390 -0.512
202403 -1.288 119.470 -1.295
202406 -1.579 120.200 -1.578
202409 -1.442 119.560 -1.449
202412 -1.051 119.950 -1.053
202503 -1.202 120.160 -1.202

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DBV Technologies  (FRA:DBV1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


DBV Technologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DBV Technologies Business Description

Traded in Other Exchanges
Address
107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

DBV Technologies Headlines

No Headlines